Legal Battle Ensues as Maker of Mounjaro Diabetes Drug Fights Counterfeit Sales

Pharmaceutical company Eli Lilly has filed lawsuits against medical spas, wellness centers, and compounding pharmacies in the US, accusing them of unlawfully marketing and selling non-FDA approved compounded products claiming to be its diabetes medication, Mounjaro. The company is seeking to protect patients and ensure the safety and effectiveness of its branded product. The FDA has not issued a compounding warning for tirzepatide, but Mounjaro has been on the FDA's Drug Shortages list. Lilly warns that compounded versions of tirzepatide can pose serious health risks as they have not been reviewed for safety, quality, or efficacy by regulatory agencies.